Education
About Us
Working with TipRanks
Follow Us
Cyclacel Pharmaceuticals (CYCC)
NASDAQ:CYCC
RESEARCH TOOLSreports
Total Valuation
Cyclacel Pharmaceuticals has a market cap or net worth of $90.30M. The enterprise value is ―.
Market Cap$90.30M
Enterprise Value―
Share Statistics
Cyclacel Pharmaceuticals has 356,357,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding356,357,540
Owned by Insiders0.05%
Owned by Institutions0.28%
Financial Efficiency
Cyclacel Pharmaceuticals’s return on equity (ROE) is 5.16 and return on invested capital (ROIC) is 516.16%.
Return on Equity (ROE)5.16
Return on Assets (ROA)-2.74
Return on Invested Capital (ROIC)516.16%
Return on Capital Employed (ROCE)5.52
Revenue Per Employee3.58K
Profits Per Employee-934.33K
Employee Count12
Asset Turnover0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cyclacel Pharmaceuticals is -0.07. Cyclacel Pharmaceuticals’s PEG ratio is >-0.01.
PE Ratio-0.07
PS Ratio0.00
PB Ratio-0.95
Price to Fair Value-0.37
Price to FCF-5.78
Price to Operating Cash Flow-0.26
PEG Ratio>-0.01
Income Statement
In the last 12 months, Cyclacel Pharmaceuticals had revenue of 43.00K and earned -11.21M in profits. Earnings per share was -5.21.
Revenue43.00K
Gross Profit43.00K
Operating Income-12.00M
Pretax Income-11.99M
Net Income-11.21M
EBITDA-12.00M
Earnings Per Share (EPS)-5.21
Cash Flow
In the last 12 months, operating cash flow was -7.99M and capital expenditures 0.00, giving a free cash flow of -7.99M billion.
Operating Cash Flow-7.99M
Free Cash Flow-7.99M
Free Cash Flow per Share-0.02
Dividends & Yields
Cyclacel Pharmaceuticals pays an annual dividend of $0.15, resulting in a dividend yield of ―
Dividend Per Share$0.15
Dividend Yield―
Payout Ratio-0.27%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change-90.16%
50-Day Moving Average0.28
200-Day Moving Average0.62
Relative Strength Index (RSI)46.69
Average Volume (3m)4.93M
Important Dates
Cyclacel Pharmaceuticals upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 7, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend DateApr 29, 2025
Financial Position
Cyclacel Pharmaceuticals as a current ratio of 0.59, with Debt / Equity ratio of 0.00%
Current Ratio0.59
Quick Ratio0.59
Debt to Market Cap0.00
Net Debt to EBITDA0.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cyclacel Pharmaceuticals has paid -782.00K in taxes.
Income Tax-782.00K
Effective Tax Rate0.07
Enterprise Valuation
Cyclacel Pharmaceuticals EV to EBITDA ratio is 0.19, with an EV/FCF ratio of 0.29.
EV to Sales-54.13
EV to EBITDA0.19
EV to Free Cash Flow0.29
EV to Operating Cash Flow0.29
Balance Sheet
Cyclacel Pharmaceuticals has $3.14M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$3.14M billion.
Cash & Marketable Securities$3.14M
Total Debt$0.00
Net Cash-$3.14M
Net Cash Per Share>-$0.01
Tangible Book Value Per Share-$1.01
Margins
Gross margin is 90.70%, with operating margin of -27916.28%, and net profit margin of -26074.42%.
Gross Margin90.70%
Operating Margin-27916.28%
Pretax Margin-27893.02%
Net Profit Margin-26074.42%
EBITDA Margin-27902.33%
EBIT Margin-27916.28%
Analyst Forecast
The average price target for Cyclacel Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast-89.76%
EPS Growth Forecast80.28%